Literature DB >> 34999833

Abnormal activation of Yap/Taz contributes to the pathogenesis of tuberous sclerosis complex.

Bethany K Terry1,2, Raehee Park1, Seo-Hee Cho3, Peter B Crino4, Seonhee Kim1.   

Abstract

The multi-systemic genetic disorder tuberous sclerosis complex (TSC) impacts multiple neurodevelopmental processes including neuronal morphogenesis, neuronal migration, myelination and gliogenesis. These alterations contribute to the development of cerebral cortex abnormalities and malformations. Although TSC is caused by mTORC1 hyperactivation, cognitive and behavioral impairments are not improved through mTORC1 targeting, making the study of the downstream effectors of this complex important for understanding the mechanisms underlying TSC. As mTORC1 has been shown to promote the activity of the transcriptional co-activator Yap, we hypothesized that altered Yap/Taz signaling contributes to the pathogenesis of TSC. We first observed that the levels of Yap/Taz are increased in human cortical tuber samples and in embryonic cortices of Tsc2 conditional knockout (cKO) mice. Next, to determine how abnormal upregulation of Yap/Taz impacts the neuropathology of TSC, we deleted Yap/Taz in Tsc2 cKO mice. Importantly, Yap/Taz/Tsc2 triple conditional knockout (tcKO) animals show reduced cortical thickness and cortical neuron cell size, despite the persistence of high mTORC1 activity, suggesting that Yap/Taz play a downstream role in cytomegaly. Furthermore, Yap/Taz/Tsc2 tcKO significantly restored cortical and hippocampal lamination defects and reduced hippocampal heterotopia formation. Finally, the loss of Yap/Taz increased the distribution of myelin basic protein in Tsc2 cKO animals, consistent with an improvement in myelination. Overall, our results indicate that targeting Yap/Taz lessens the severity of neuropathology in a TSC animal model. This study is the first to implicate Yap/Taz as contributors to cortical pathogenesis in TSC and therefore as potential novel targets in the treatment of this disorder.
© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34999833      PMCID: PMC9239747          DOI: 10.1093/hmg/ddab374

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   5.121


  87 in total

1.  mTORC1 promotes proliferation of immature Schwann cells and myelin growth of differentiated Schwann cells.

Authors:  Bogdan Beirowski; Keit Men Wong; Elisabetta Babetto; Jeffrey Milbrandt
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-08       Impact factor: 11.205

2.  Fiji: an open-source platform for biological-image analysis.

Authors:  Johannes Schindelin; Ignacio Arganda-Carreras; Erwin Frise; Verena Kaynig; Mark Longair; Tobias Pietzsch; Stephan Preibisch; Curtis Rueden; Stephan Saalfeld; Benjamin Schmid; Jean-Yves Tinevez; Daniel James White; Volker Hartenstein; Kevin Eliceiri; Pavel Tomancak; Albert Cardona
Journal:  Nat Methods       Date:  2012-06-28       Impact factor: 28.547

3.  YAP mediates crosstalk between the Hippo and PI(3)K–TOR pathways by suppressing PTEN via miR-29.

Authors:  Karen Tumaneng; Karin Schlegelmilch; Ryan C Russell; Dean Yimlamai; Harihar Basnet; Navin Mahadevan; Julien Fitamant; Nabeel Bardeesy; Fernando D Camargo; Kun-Liang Guan
Journal:  Nat Cell Biol       Date:  2012-12       Impact factor: 28.824

4.  Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin.

Authors:  Robert P Carson; Dominic L Van Nielen; Peggy A Winzenburger; Kevin C Ess
Journal:  Neurobiol Dis       Date:  2011-08-26       Impact factor: 5.996

5.  Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity.

Authors:  Lei Liu; Yan Luo; Long Chen; Tao Shen; Baoshan Xu; Wenxing Chen; Hongyu Zhou; Xiuzhen Han; Shile Huang
Journal:  J Biol Chem       Date:  2010-10-11       Impact factor: 5.157

6.  An FAK-YAP-mTOR Signaling Axis Regulates Stem Cell-Based Tissue Renewal in Mice.

Authors:  Jimmy Kuang-Hsien Hu; Wei Du; Samuel J Shelton; Michael C Oldham; C Michael DiPersio; Ophir D Klein
Journal:  Cell Stem Cell       Date:  2017-04-27       Impact factor: 24.633

7.  Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function.

Authors:  Lynsey Meikle; Kristen Pollizzi; Anna Egnor; Ioannis Kramvis; Heidi Lane; Mustafa Sahin; David J Kwiatkowski
Journal:  J Neurosci       Date:  2008-05-21       Impact factor: 6.167

Review 8.  Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex.

Authors:  Filipe Palavra; Conceição Robalo; Flávio Reis
Journal:  Oxid Med Cell Longev       Date:  2017-03-12       Impact factor: 6.543

9.  PARD3 dysfunction in conjunction with dynamic HIPPO signaling drives cortical enlargement with massive heterotopia.

Authors:  Wenying Angela Liu; She Chen; Zhizhong Li; Choong Heon Lee; Ghayda Mirzaa; William B Dobyns; M Elizabeth Ross; Jiangyang Zhang; Song-Hai Shi
Journal:  Genes Dev       Date:  2018-06-13       Impact factor: 11.361

10.  Centrosome anchoring regulates progenitor properties and cortical formation.

Authors:  Wei Shao; Jiajun Yang; Ming He; Xiang-Yu Yu; Choong Heon Lee; Zhaohui Yang; Alexandra L Joyner; Kathryn V Anderson; Jiangyang Zhang; Meng-Fu Bryan Tsou; Hang Shi; Song-Hai Shi
Journal:  Nature       Date:  2020-03-25       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.